Jeremy Bender, Day One Biopharmaceuticals CEO

FDA gives ac­cel­er­at­ed ap­proval to Day One’s tar­get­ed treat­ment for most com­mon brain tu­mor in kids

The FDA grant­ed ac­cel­er­at­ed ap­proval to Day One Bio­phar­ma­ceu­ti­cals’ pe­di­atric brain tu­mor treat­ment.

The reg­u­la­tor on Tues­day ap­proved tovo­rafenib, tak­ing place …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.